Literature DB >> 1659573

In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.

L Ossowski1, G Clunie, M T Masucci, F Blasi.   

Abstract

Numerous studies have linked the production of increased levels of urokinase type plasminogen activator (uPA) with the malignant phenotype. It has also been shown that a specific cell surface receptor can bind uPA through a domain distinct and distant from the proteolytic domain. In an in vivo model of invasion, consisting of experimentally modified chorioallantoic membrane (CAM) of a chick embryo, only cells that concurrently expressed both uPA and a receptor for uPA, and in which the receptor was saturated with uPA, were efficient in invasion. To test whether uPA produced by one cell can, in a paracrine fashion, affect the invasive capacity of a receptor-expressing cell, we transfected LB6 mouse cells with human uPA (LB6[uPA]), or human uPA-receptor cDNA (LB6[uPAR]). LB6(uPA) cells released into the medium 1-2 Ploug units of human uPA per 10(6) cells in 24 h. The LB6(uPAR) cells expressed on their surface approximately 12,000 high affinity (Kd 1.7 x 10(-10) M uPA binding sites per cell. Unlabeled LB6(uPA) and 125-IUdR-labeled LB6(uPAR) cells were coinoculated onto experimentally wounded and resealed CAMs and their invasion was compared to that of homologous mixtures of labeled and unlabeled LB6(uPAR) or LB6(uPA) cells. Concurrent presence of both cell types in the CAMs resulted in a 1.8-fold increase of invasion of the uPA-receptor expressing cells. A four-fold stimulation of invasion was observed when cells were cocultured in vitro, prior to in vivo inoculation. Enhancement of invasion was prevented in both sets of experiments by treatment with specific antihuman uPA antibodies, indicating that uPA was the main mediator of the invasion-enhancing, paracrine effect on the receptor-expressing cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659573      PMCID: PMC2289942          DOI: 10.1083/jcb.115.4.1107

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  44 in total

1.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas.

Authors:  P Basset; J P Bellocq; C Wolf; I Stoll; P Hutin; J M Limacher; O L Podhajcer; M P Chenard; M C Rio; P Chambon
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.

Authors:  W Schlechte; G Murano; D Boyd
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

3.  Metalloproteinases and malignant conversion: does correlation imply causality?

Authors:  L A Liotta; W Stetler-Stevenson
Journal:  J Natl Cancer Inst       Date:  1989-04-19       Impact factor: 13.506

4.  Tissue cooperation in a proteolytic cascade activating human interstitial collagenase.

Authors:  C S HE; S M Wilhelm; A P Pentland; B L Marmer; G A Grant; A Z Eisen; G I Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

6.  Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells.

Authors:  S Yagel; A H Warner; H N Nellans; P K Lala; C Waghorne; D T Denhardt
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

7.  Characterization of the cellular binding site for the urokinase-type plasminogen activator.

Authors:  A Estreicher; A Wohlwend; D Belin; W D Schleuning; J D Vassalli
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

8.  Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.

Authors:  H R Yu; R M Schultz
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

9.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

10.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.

Authors:  L Ossowski; H Russo-Payne; E L Wilson
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

View more
  50 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 3.  Astrocytes and axon regeneration in the central nervous system.

Authors:  J Fawcett
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

Review 4.  The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1997-02

5.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

6.  Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells.

Authors:  T Abe; T Mori; K Kohno; M Seiki; T Hayakawa; H G Welgus; S Hori; M Kuwano
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

7.  Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.

Authors:  Takuya Akai; Kenji Niiya; Nobuo Sakuragawa; Hideaki Iizuka; Shunro Endo
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

8.  Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.

Authors:  D M Evans; K Sloan-Stakleff; M Arvan; D P Guyton
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

9.  Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.

Authors:  Efrem Mebrahtu; Alexander Zheleznyak; Minjun A Hur; Richard Laforest; Suzanne E Lapi
Journal:  Nucl Med Biol       Date:  2012-11-12       Impact factor: 2.408

10.  Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.

Authors:  S N Wagner; M J Atkinson; C Wagner; H Höfler; M Schmitt; O Wilhelm
Journal:  Histochem Cell Biol       Date:  1996-01       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.